PDSB
PDS Biotechnology Corporation Common Stock
stockNASDAQ
pds biotechnology is a clinical stage biopharmaceutical company developing the next-generation of simpler, safer and more effective immunotherapies for cancer and infectious diseases. pds biotechnology's proprietary versamune® platform vector is based on synthetic and biodegradable lipids which possess a very specific structure and positive charge. the lipids form nanoparticles which activate and are taken up very efficiently by the immune system. the therapeutic product consists of versamune® formulated with a harmless form of the protein or disease-causing agent associated with the particular disease (the antigen) which our immune systems can recognize and respond to. this antigen could be a unique protein expressed only in the cancer cells and not in healthy cells, or it could be a specific viral protein(s) from an infectious virus for example. pds is in the process of completing its first phase 1 human clinical trial in 2015 for pds0101, and has initiated design and preparati
| Period | Price | Date | Change | Beta |
|---|---|---|---|---|
| 1W | 0.75 | 2026-10-02 | +73.01% | 31.231 |
| 1M | 0.29 | 2026-09-09 | +341.98% | -6.218 |
| 3M | 0.79 | 2026-07-09 | +64.51% | -0.168 |
| 6M | 1.07 | 2026-04-09 | +21.03% | 1.700 |
| 1Y | 0.99 | 2025-10-09 | +31.35% | 2.510 |
| 2Y | 3.40 | 2024-10-09 | -61.91% | — |
| 5Y | 13.57 | 2021-10-08 | -90.46% | 1.939 |
PDS Biotechnology Corporation Common Stock (NASDAQ:PDSB) stock price today is $1.30, and today's volume is 9,656,039. PDSB is up 26.961% today. The 30 day average volume is 47.55M. PDSB market cap is $93.85M with 72.47M shares outstanding.